Sherbrooke Park Advisers’s Verve Therapeutics VERV Stock Holding History

Sherbrooke Park Advisers’s Portfolio VERV Stock Details VERV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-13,215	Closed	-$148K	–	731
2025 Q2	$148K	Sell	13,215 -6,618	-33%	-$37.7K	0.06%	424
2025 Q1	$90.6K	Buy	+19,833	New	+$133K	0.04%	524
2024 Q4	–	Sell	-76,384	Closed	-$370K	–	1182
2024 Q3	$370K	Buy	76,384 +54,913	+256%	+$319K	0.08%	468
2024 Q2	$105K	Buy	+21,471	New	+$135K	0.02%	833

Other funds holding VERV

GCM

Greenland Capital Management New York $787M AUM 40.68% 1-Year Est. Return

DekaBank Deutsche Girozentrale Frankfurt, Germany $59.2B AUM 26.02% 1-Year Est. Return

BIG

Brooklyn Investment Group Brooklyn, New York $3.2B AUM 26.32% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

Sherbrooke Park Advisers's VERV Position: Q3 2025 in Review

Sherbrooke Park Advisers sold out of Verve Therapeutics (VERV) in Q3 2025, closing a stake of 13,215 shares — an estimated $148K sold.

Sherbrooke Park Advisers first reported a position in VERV in Q2 2024 and held it in 4 quarters. The position peaked at $370K in Q3 2024. 6 funds tracked by Wall St. Rank hold VERV as of Q3 2025.

Sherbrooke Park Advisers reported no remaining Verve Therapeutics position as of Q3 2025 after selling out during the quarter.
Sherbrooke Park Advisers sold 13,215 Verve Therapeutics shares in Q3 2025, an estimated $148K.
Sherbrooke Park Advisers first reported a position in Verve Therapeutics in Q2 2024 and held it in 4 quarters.
Sherbrooke Park Advisers's Verve Therapeutics position peaked at $370K in Q3 2024.
6 funds tracked by Wall St. Rank held Verve Therapeutics as of Q3 2025.

Based on Sherbrooke Park Advisers's 13F filing for Q3 2025, filed 14 Nov 2025.